نتائج البحث - "Geertsen, Poul F."

1

مؤتمر

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.

المصدر: McDermott , D F , Lee , J-L , Bjarnason , G A , Larkin , J M G , Gafanov , R A , Kochenderfer , M D , Jensen , N V , Donskov , F , Malik , J , Poprach , A , Tykodi , S S , Gordoa , T A , Cho , D C , Geertsen , P F , Duran , M A C , Simone , C D , Du , X , Perini , R F , Rodriguez-Lopez , K & Atkins , M B 2020 , ' First-line ....

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/c5030676-a743-4298-97b4-654c3752ce72Test

الإتاحة: https://doi.org/10.1200/JCO.2020.38.15_suppl.5069Test
https://portal.findresearcher.sdu.dk/da/publications/c5030676-a743-4298-97b4-654c3752ce72Test

View record in BASE

2

دورية أكاديمية

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

المصدر: McDermott , D F , Lee , J L , Bjarnason , G A , Larkin , J M G , Gafanov , R A , Kochenderfer , M D , Jensen , N V , Donskov , F , Malik , J , Poprach , A , Tykodi , S S , Alonso-Gordoa , T , Cho , D C , Geertsen , P F , Climent Duran , M A , DiSimone , C , Silverman , R K , Perini , R F , Schloss , C & Atkins , M B 2021 , ' Open-Label, ....

مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, Carcinoma, Renal Cell/drug therapy, Female, Follow-Up Studies, Humans, Kidney Neoplasms/drug therapy, Male, Middle Aged, Non-Randomized Controlled Trials as Topic, Prognosis, Survival Rate

وصف الملف: application/pdf

العلاقة: https://pure.au.dk/portal/en/publications/bae5aee9-7f1b-4552-855b-cfdb62d318f9Test

الإتاحة: https://doi.org/10.1200/JCO.20.02363Test
https://pure.au.dk/portal/en/publications/bae5aee9-7f1b-4552-855b-cfdb62d318f9Test
https://pure.au.dk/ws/files/274416924/jco.20.02363.pdfTest
http://www.scopus.com/inward/record.url?scp=85103228704&partnerID=8YFLogxKTest

View record in BASE

3

دورية أكاديمية

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

المصدر: McDermott , D F , Lee , J L , Bjarnason , G A , Larkin , J M G , Gafanov , R A , Kochenderfer , M D , Jensen , N V , Donskov , F , Malik , J , Poprach , A , Tykodi , S S , Alonso-Gordoa , T , Cho , D C , Geertsen , P F , Climent Duran , M A , DiSimone , C , Silverman , R K , Perini , R F , Schloss , C & Atkins , M B 2021 , ' Open-Label, ....

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/e4f4b67a-a03e-4542-97e0-859460da4b16Test

الإتاحة: https://doi.org/10.1200/JCO.20.02363Test
https://portal.findresearcher.sdu.dk/da/publications/e4f4b67a-a03e-4542-97e0-859460da4b16Test
https://findresearcher.sdu.dk/ws/files/181944398/jco.20.02363.pdfTest

View record in BASE

4

دورية أكاديمية

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma:42-month follow-up of a randomized phase 3 clinical trial

المصدر: Motzer , R J , Escudier , B , McDermott , D F , Arén Frontera , O , Melichar , B , Powles , T , Donskov , F , Plimack , E R , Barthélémy , P , Hammers , H J , George , S , Grünwald , V , Porta , C , Neiman , V , Ravaud , A , Choueiri , T K , Rini , B I , Salman , P , Kollmannsberger , C K , Tykodi , S S , Grimm , M O , Gurney , H , Leibowitz-Amit ....

مصطلحات موضوعية: clinical trials, phase III as topic, CTLA-4 antigen, immunotherapy, kidney neoplasms, programmed cell death 1 receptor

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1136/jitc-2020-000891Test
https://researchers.mq.edu.au/en/publications/16efdcde-4b5e-4c18-804a-e2d1896c4c6aTest
https://research-management.mq.edu.au/ws/files/127646137/Publisher_version_open_access_.pdfTest
http://www.scopus.com/inward/record.url?scp=85088040485&partnerID=8YFLogxKTest

View record in BASE

5

دورية أكاديمية

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

المساهمون: Bristol Myers Squibb and ONO Pharmaceutical Company Limited

المصدر: Journal for ImmunoTherapy of Cancer ; volume 8, issue 2, page e000891 ; ISSN 2051-1426

الإتاحة: https://doi.org/10.1136/jitc-2020-000891Test

View record in BASE

6

دورية أكاديمية

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

المؤلفون: Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, SuÃ¡rez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel, Universitat AutÃ²noma de Barcelona

وصف الملف: application/pdf

العلاقة: British Journal of Cancer; Vol. 119 (september 2018), p. 663-669; https://ddd.uab.cat/record/228008Test; urn:10.1038/s41416-018-0164-0; urn:oai:ddd.uab.cat:228008; urn:pmid:30197417; urn:pmcid:PMC6173766; urn:pmc-uid:6173766; urn:articleid:15321827v119p663; urn:scopus_id:85053437700; urn:oai:pubmedcentral.nih.gov:6173766

الإتاحة: https://ddd.uab.cat/record/228008Test

View record in BASE

النص الكامل

7

دورية أكاديمية

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

المؤلفون: Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, Suarez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel

المصدر: Powles , T , Motzer , R J , Escudier , B , Pal , S , Kollmannsberger , C , Pikiel , J , Gurney , H , Rha , S Y , Park , S H , Geertsen , P F , Gross-Goupil , M , Grande , E , Suarez , C , Markby , D W , Arroyo , A , Dean , M , Choueiri , T K & George , D 2018 , ' Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell ....

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1038/s41416-018-0164-0Test
https://researchers.mq.edu.au/en/publications/0c40e1f4-5980-424e-8b52-88b8d9cdbb4fTest
https://research-management.mq.edu.au/ws/files/93756563/Publisher_version_open_access_.pdfTest
http://www.scopus.com/inward/record.url?scp=85053437700&partnerID=8YFLogxKTest

View record in BASE

8

دورية أكاديمية

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

المؤلفون: Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, Suarez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel

المصدر: British Journal of Cancer ; volume 119, issue 6, page 663-669 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-018-0164-0Test
http://www.nature.com/articles/s41416-018-0164-0Test
http://www.nature.com/articles/s41416-018-0164-0.pdfTest

View record in BASE

9

دورية أكاديمية

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma:Results from DARENCA study 2

المؤلفون: Soerensen, Anne V, Geertsen, Poul F, Christensen, Ib J, Hermann, Gregers G, Jensen, Niels V, Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede

المصدر: Soerensen , A V , Geertsen , P F , Christensen , I J , Hermann , G G , Jensen , N V , Fode , K , Petersen , A , Sandin , R & Donskov , F 2016 , ' A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma : Results from DARENCA study 2 ' , Acta Oncologica , vol. 55 , no. 3 , pp. 341-348 . https://doi.org/10.3109/0284186X.2015.1091499Test

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/4e963283-937e-4ced-8f2f-414ef4d50a3eTest

الإتاحة: https://doi.org/10.3109/0284186X.2015.1091499Test
https://portal.findresearcher.sdu.dk/da/publications/4e963283-937e-4ced-8f2f-414ef4d50a3eTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819832/pdf/ionc-55-341.pdfTest

View record in BASE

10

دورية أكاديمية

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma:Results from DARENCA study 2

المؤلفون: Soerensen, Anne V, Geertsen, Poul F, Christensen, Ib J, Hermann, Gregers G, Jensen, Niels V, Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede

المصدر: Soerensen , A V , Geertsen , P F , Christensen , I J , Hermann , G G , Jensen , N V , Fode , K , Petersen , A , Sandin , R & Donskov , F 2016 , ' A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma : Results from DARENCA study 2 ' , Acta Oncologica , vol. 55 , no. 3 , pp. 341-348 . https://doi.org/10.3109/0284186X.2015.1091499Test

وصف الملف: application/pdf

العلاقة: https://vbn.aau.dk/da/publications/c8d6d080-5a92-487e-8ee4-6f23cab27cd7Test

الإتاحة: https://doi.org/10.3109/0284186X.2015.1091499Test
https://vbn.aau.dk/da/publications/c8d6d080-5a92-487e-8ee4-6f23cab27cd7Test
https://vbn.aau.dk/ws/files/269868125/A_five_factor_biomarker_profile_obtained_week_4_12_of_treatment_for_improved_prognostication_in_metastatic_renal_cell_carcinoma_Results_from_DARENCA.pdfTest

View record in BASE

تنقيح النتائج